Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12309458 | 0.89 | ALDH1A1 (0.53) | ALDH1A1CYP1A2SLC2A1ADRA2ARAD52 | |
| SCHEMBL14443020 | 0.89 | ALDH1A1 (0.53) | ALDH1A1CYP1A2SLC2A1ADRA2ARAD52 | |
| SCHEMBL14443017 | 0.89 | ALDH1A1 (0.53) | ALDH1A1CYP1A2SLC2A1ADRA2ARAD52 | |
| SCHEMBL20079226 | 0.84 | CYP1A2 (0.55) | ALDH1A1CYP1A2SLC2A1ADRA2A | |
| SCHEMBL10289039 | 0.81 | ALDH1A1 (0.49) | ALDH1A1CYP1A2SLC2A1 | |
| SCHEMBL19376421 | 0.80 | CYP1A2 (0.57) | ALDH1A1CYP1A2ADRA2A | |
| SCHEMBL10241565 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP1A2SLC2A1RAD52 | |
| SCHEMBL14755652 | 0.78 | CYP1A2 (0.47) | ALDH1A1CYP1A2SLC2A1ADRA2A | |
| SCHEMBL14443019 | 0.77 | CYP1A2 (0.41) | ALDH1A1CYP1A2 | |
| SCHEMBL14454185 | 0.77 | CYP1A2 (0.41) | ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| US-10975076-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119654-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7652028-B2 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | INOTEK PHARMACEUTICALS CORPORATION | 2010-01-07 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975076-B2 | Compositions, uses and methods for making them | BAX, CASP3, CASP7 | ALDH1A1 1878/4885CYP1A2 651/4885SLC2A1 4395/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | ALDH1A1 137/4885CYP1A2 507/4885SLC2A1 1629/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | ALDH1A1 137/4885CYP1A2 507/4885SLC2A1 1629/4885 |
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, CASP7 | ALDH1A1 2282/4885CYP1A2 1418/4885SLC2A1 4397/4885 |
| US-20100004220-A1 | Indenoisoquinolinone Analogs and Methods of Use Thereof | TNNI3, IDH2, GLS | ALDH1A1 137/4885CYP1A2 507/4885SLC2A1 1629/4885 |
| US-20100179140-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | ALDH1A1 137/4885CYP1A2 507/4885SLC2A1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.